Summit Corporation plc
('Summit' or 'the Company')
SUMMIT TO PRESENT AT THE COWEN AND COMPANY 34th ANNUAL HEALTHCARE CONFERENCE
Oxford, UK, 26 February 2014 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, announces that it will be presenting at the Cowen and Company 34th Annual Healthcare Conference in Boston on Wednesday 5 March at 11:00 ET (16:00 GMT).
Mr Glyn Edwards, the Chief Executive Officer, will provide a Company overview and highlight its clinical candidates SMT C1100 for the treatment of DMD and SMT19969 for the treatment of CDI. A copy of the presentation will be available shortly after the event from the Investors section of the Company's website at www.summitplc.com.
- END -
Notes to Editors
About Summit
Summit is an Oxford, UK based drug discovery and development Company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and follow Summit on Twitter (@summitplc).
For more information, please contact:
| Summit Glyn Edwards / Richard Pye | Tel: +44 (0)1235 443 951 |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson | Tel: +44 (0)207 7148 7900 |
| Hybridan LLP (Broker) Claire Louise Noyce / William Lynne | Tel: +44 (0)207 947 4350 |
| Peckwater PR (Financial public relations, UK) Tarquin Edwards | Tel: +44 (0)7879 458 364 tarquin.edwards@peckwaterpr.co.uk |
| MacDougall Biomedical Communications (US media contact) Michelle Avery | Tel: +1 781-235-3060 |